Edgewise Therapeutics, Inc. (EWTX) Stock Price & How to Invest
Last updated November 2026
Short answer
EWTX is Edgewise Therapeutics, a clinical-stage biotech developing muscle-targeted small molecules for heart disease, so investing in it means underwriting trial readouts rather than current profits. In 2026 it sold its lead drug, sevasemten, and the rest of its muscular dystrophy business to Servier, and it is now built around EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure, with about $1.74 billion of cash and investments as of September 30, 2026. As of November 20, 2026 the shares closed near $40, up about 70% in 2026 and about 81% over the past year, for a market value of roughly $4.4 billion, with an EDG-7500 Phase 3 trial expected to start by the end of 2026.
EWTX stock price
As of 2026-11-20, Edgewise Therapeutics, Inc. (EWTX) last closed at $39.90, up 76.0% over the past year. Over the past 52 weeks it has traded between $20.94 and $48.74.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Edgewise Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
EWTX key stats
At $39.91 on November 20, 2026, Edgewise Therapeutics, Inc. (EWTX) has a market cap of $4.4B and a P/E of 4.8 on trailing earnings.
- Market cap
- $4.4B
- P/E (trailing)
- 4.8
- EPS (trailing 12 months)
- $8.38
- Price to book
- 2.7
- Beta
- 0.40
Market cap, P/E and yield are measured at the $39.91 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Edgewise Therapeutics, Inc. (EWTX)?
The last two weeks for Edgewise Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- EWTX closed at $39.90 on November 20, 2026, down 13.1% over the past five trading days (from $45.93).
Edgewise Therapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Edgewise Therapeutics, Inc. (EWTX) do?
Edgewise Therapeutics (Nasdaq: EWTX) is a Boulder, Colorado clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle for serious cardiac conditions. Until mid-2026 its lead candidate was sevasemten (formerly EDG-5506), a skeletal myosin inhibitor for Becker and Duchenne muscular dystrophy. In a deal that closed in July 2026, Edgewise sold sevasemten and its muscular dystrophy business to Servier, receiving about $1.4 billion in cash at closing (Servier has described a $1.55 billion upfront), with up to about $1.1 billion more in potential regulatory and commercial milestones reported alongside it. On November 4, 2026 Servier said the 18-month GRAND CANYON study of sevasemten in Becker did not meet its primary endpoint, the North Star Ambulatory Assessment, or its secondary endpoints, while safety remained favourable. Edgewise had already been paid, so the failure falls on Servier, though it makes the sevasemten milestones much less likely to be earned.
What remains is a cardiology company. EDG-7500 is a cardiac sarcomere modulator that posted positive 12-week Phase 2 CIRRUS-HCM data in obstructive and nonobstructive hypertrophic cardiomyopathy, presented at the ESC Congress in August 2026. On November 5 Edgewise reported a productive End-of-Phase 2 meeting with the FDA and said the Phase 3 protocol uses tolerability-based dose escalation without safety echocardiogram monitoring, a practical difference from the first-generation cardiac myosin inhibitors, and the trial is expected to start by year-end 2026. A third program, the cardiac sarcomere modulator EDG-15400, dosed its first patient in the Phase 2 EQUINOX-HFpEF trial in heart failure with preserved ejection fraction in October 2026.
The sale reshaped the financials. Third-quarter 2026 net income was about $1.17 billion, or $9.65 per diluted share, entirely from a roughly $1.35 billion one-time gain on the sale less about $155 million of income tax, so the trailing P/E near 5 that data services show means nothing about the operating business. Operating costs fell, with R&D of about $31.6 million against $37.5 million a year earlier, while G&A rose to about $14.6 million from $9.4 million. Cash and investments were about $1.74 billion on September 30, 2026, up from about $530 million at the end of 2025, against debt of about $3 million. The stock closed near $40 on November 20, 2026, up about 70% year to date and about 81% over twelve months but about 9% lower over three months, for a market value of about $4.4 billion, roughly 2.7 times book value. Analysts expect the operating loss to resume at about $0.43 per share in the fourth quarter and about $1.86 per share in 2027.
What's driving Edgewise Therapeutics, Inc. (EWTX)?
1. EDG-7500 in hypertrophic cardiomyopathy
EDG-7500 is a cardiac sarcomere modulator designed to reduce outflow obstruction while limiting the drop in heart pumping function that has dogged the first-generation cardiac myosin inhibitors. Positive 12-week Phase 2 CIRRUS-HCM data in mid-2026 showed gradient and biomarker improvements with no readings of ejection fraction below 50 percent. After a November 2026 End-of-Phase 2 meeting with the FDA, Edgewise said its Phase 3 protocol will use tolerability-based dose escalation without safety echo monitoring, which, if it carries into a label, could make the drug simpler to prescribe than mavacamten. The Phase 3 trial in obstructive and nonobstructive HCM is expected to start by the end of 2026 and is now the company's main value driver.
2. The Servier sale and what it left behind
Selling sevasemten and the muscular dystrophy business to Servier converted the company's most advanced asset into about $1.4 billion of cash at closing, and the timing looks fortunate in hindsight: Servier reported in November 2026 that the GRAND CANYON study in Becker missed its primary endpoint. Edgewise no longer carries the cost or the risk of that program, and R&D spending fell year over year in the third quarter. Potential milestones of about $1.1 billion were reported alongside the deal, but a failed 18-month study makes the regulatory and commercial milestones tied to sevasemten unlikely in the near term, and their exact terms have not been detailed in Edgewise's results release.
3. EDG-15400 and the HFpEF opportunity
EDG-15400 moved into Phase 2 in October 2026, when the first patient was dosed in EQUINOX-HFpEF, a randomized, double-blind, placebo-controlled trial in adults with symptomatic heart failure with preserved ejection fraction. HFpEF is a far larger population than HCM and has few effective treatments, so even early data could move the stock, though it is also a field where many drug programs have failed. Earlier platform candidates such as EDG-003 give further shots on goal but contribute little near-term value.
4. Balance-sheet strength
With about $1.74 billion in cash and investments as of September 30, 2026, minimal debt, and an operating spend now around $46 million a quarter (R&D plus G&A), Edgewise can fund the EDG-7500 Phase 3 and the EDG-15400 Phase 2 for years without needing to raise equity. Cash covers roughly 40% of the $4.4 billion market value, which limits financing dilution risk and gives the company room to add programs, though it also raises the question of how the cash will be used.
What are the risks to Edgewise Therapeutics, Inc. (EWTX)?
As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value now depends almost entirely on two cardiac programs, so a disappointing EDG-7500 Phase 3 or an FDA setback would remove most of the expected value above cash. The company sold its most advanced asset, which removed one shot on goal along with its risk, and the GRAND CANYON failure means the sevasemten milestones are unlikely to add much. The HCM field is crowded with better-capitalized rivals, including Bristol Myers Squibb's approved Camzyos and Cytokinetics' aficamten, so EDG-7500 must show a genuinely differentiated safety and efficacy profile to matter commercially. HFpEF has a long record of failed trials, and EDG-15400 is still at an early stage. Trailing earnings figures are distorted by the one-time gain on the Servier sale, and analysts expect losses of about $1.86 per share in 2027, so the trailing P/E near 5 is not a measure of value. G&A costs rose about 55% year over year in the third quarter. The shares have fallen about 9% over three months even after the sale, and they can move sharply on trial news, competitor data or decisions about how the cash is deployed.
What is the Edgewise Therapeutics, Inc. (EWTX) forecast?
12 analysts publish price targets on EWTX, averaging $55.42 as of November 2026, or +38.9% against the $39.91 share price on November 20, 2026. The published targets run from $36.00 to $85.00, a wide spread, and the ratings split 12 buy, 1 hold, 0 sell. Over the last six months there have been 8 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full EWTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is EWTX a buy or a sell?
We give no verdict on Edgewise Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. EDG-7500 in hypertrophic cardiomyopathy. EDG-7500 is a cardiac sarcomere modulator designed to reduce outflow obstruction while limiting the drop in heart pumping function that has dogged the first-generation cardiac myosin inhibitors. The most optimistic published target, $85.00, assumes this works close to its best case.
The case against. As a pre-revenue clinical-stage biotech, Edgewise has no approved products and its value now depends almost entirely on two cardiac programs, so a disappointing EDG-7500 Phase 3 or an FDA setback would remove most of the expected value above cash. The most pessimistic target, $36.00, is roughly what EWTX is worth if this bites instead.
Read the full bull and bear case on EWTX, including what would have to change to break either one. Walnut is not an investment adviser.
Has Edgewise Therapeutics, Inc. (EWTX) split its stock?
No. Edgewise Therapeutics, Inc. (EWTX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Edgewise Therapeutics, Inc. (EWTX) valued?
Market cap, P/E and dividend yield at today's price are in the EWTX key stats above. The business figures below come from Edgewise Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Product revenue: ~$0 (pre-commercial)
- Cash & investments (September 30, 2026): ~$1.74B after the Servier sale; debt ~$3M
- Q3 2026 net income: ~$1.17B ($9.65 diluted EPS), from a ~$1.35B one-time gain on the sale less ~$155M tax
- Q3 2026 operating expenses: R&D ~$31.6M (vs ~$37.5M), G&A ~$14.6M (vs ~$9.4M)
- Forward EPS: Q4 2026 consensus ~-$0.43; 2027 ~-$1.86
As of November 2026: Edgewise generates no product revenue, so traditional valuation multiples do not apply, and the trailing P/E near 5 reflects only the one-time gain on the Servier sale. Subtracting about $1.74 billion of cash from the roughly $4.4 billion market value leaves an enterprise value near $2.7 billion for EDG-7500, EDG-15400 and the platform. Analysts average a $55.42 target across 12 analysts with a strong buy rating, and Wedbush trimmed its target to $51 from $53 in November 2026 while keeping an outperform rating.
Who competes with Edgewise Therapeutics, Inc. (EWTX)?
Cardiac myosin and sarcomere modulators
In hypertrophic cardiomyopathy, EDG-7500 competes against Bristol Myers Squibb's approved Camzyos (mavacamten) and Cytokinetics' aficamten, both first-generation cardiac myosin inhibitors with far larger commercial and financial resources. Edgewise's pitch is a differentiated mechanism that aims to avoid the ejection-fraction reductions seen with those drugs, and a Phase 3 design without safety echo monitoring that could make it easier to use.
Heart failure with preserved ejection fraction
EDG-15400 enters HFpEF, where large pharmaceutical companies sell or are developing drugs from several classes, including SGLT2 inhibitors and GLP-1-based therapies, and where many novel mechanisms have failed in trials. Edgewise exited muscular dystrophy when it sold sevasemten to Servier, so companies such as Sarepta Therapeutics, PTC Therapeutics and Solid Biosciences are no longer direct rivals.
Broader clinical-stage cardiovascular biotech
More generally EWTX competes for investor capital and clinical talent with the wider universe of pre-revenue cardiovascular and rare-disease biotechs, where scarce specialist funding flows toward the programs with the strongest data and clearest regulatory path. Its large cash balance is unusual for a company of its stage.
What stocks are similar to Edgewise Therapeutics, Inc. (EWTX)?
Other names that sit close to EWTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Edgewise Therapeutics, Inc. (EWTX)
There are three common ways to get EWTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so EWTX sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where EWTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Edgewise Therapeutics, Inc. (EWTX)
Edgewise is a cash-rich, pre-revenue clinical biotech whose story now lives and dies on cardiac trial data, not earnings. The Servier sale turned its muscular dystrophy program into about $1.4 billion of cash at closing, and Servier's November 2026 report that sevasemten missed its primary endpoint in Becker muscular dystrophy left that risk with the buyer, though it likely puts the milestone payments tied to the drug in doubt. About 40% of the market value is now cash, and the rest is a bet on EDG-7500 and EDG-15400. Walnut is not an investment adviser.
More on Edgewise Therapeutics, Inc. (EWTX)
Whether EWTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EWTX a buy or a sell?, and where the stock could go from here in the EWTX stock forecast.
For income investors, whether EWTX pays a dividend and how the payout looks is covered in does EWTX pay a dividend? And to weigh EWTX against a peer, read the full side-by-side comparisons: EWTX vs BMY and EWTX vs SRPT.
Wondering how EWTX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Edgewise Therapeutics, Inc.
Ask Walnut's AI anything about EWTX and see how it fits what you own.
FAQ
What does Edgewise Therapeutics do?
+
Edgewise is a clinical-stage biopharmaceutical company developing orally administered small molecules that target muscle. After selling its muscular dystrophy business to Servier in 2026, its programs focus on serious cardiac conditions: EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for heart failure with preserved ejection fraction.
Is EWTX profitable?
+
Not on an operating basis. Edgewise has no approved products and no product revenue, and it lost about $49.0 million in the first quarter of 2026 and about $57.3 million in the second. Third-quarter net income of about $1.17 billion came entirely from a one-time gain on selling sevasemten to Servier. Analysts expect losses to resume, at about $0.43 per share in the fourth quarter and about $1.86 per share in 2027.
What is sevasemten?
+
Sevasemten (formerly EDG-5506) is a skeletal myosin inhibitor that Edgewise developed for Becker and Duchenne muscular dystrophy. Edgewise sold it, along with its muscular dystrophy business, to Servier in a deal that closed in July 2026, receiving about $1.4 billion at closing. In November 2026 Servier reported that the 18-month GRAND CANYON study in Becker did not meet its primary or secondary endpoints, though safety remained favourable.
What is EDG-7500?
+
EDG-7500 is Edgewise's cardiac sarcomere modulator for hypertrophic cardiomyopathy and now its lead program. It posted positive 12-week Phase 2 CIRRUS-HCM data in mid-2026. After an End-of-Phase 2 meeting with the FDA in November 2026, Edgewise said the Phase 3 protocol uses tolerability-based dose escalation without safety echo monitoring, and it expects the trial to start by year-end 2026.
How much cash does Edgewise have?
+
Edgewise reported about $1.74 billion in cash and investments as of September 30, 2026, up from about $530 million at the end of 2025, after receiving roughly $1.4 billion from the Servier sale. Debt is about $3 million. With third-quarter R&D and G&A of about $46 million combined, the cash covers many years of spending at the current pace, though a Phase 3 trial will raise costs.
Does EWTX pay a dividend?
+
No. Like most clinical-stage biotechs, Edgewise pays no dividend and reinvests its capital into research and development. Even after the Servier sale lifted cash to about $1.74 billion, the company has said nothing about returning it to shareholders; it is directed toward advancing its cardiac pipeline.
Why is EWTX considered a high-risk stock?
+
The company's value depends heavily on clinical trial outcomes and regulatory decisions rather than current earnings, and after selling sevasemten it rests mainly on EDG-7500 and EDG-15400. A disappointing Phase 3 HCM result or a failed HFpEF study could move the share price sharply, which is common for pre-revenue biotech. Cash of about $1.74 billion, roughly 40% of the market value, provides more of a floor than most peers have.
Who competes with Edgewise?
+
In hypertrophic cardiomyopathy it competes with Bristol Myers Squibb's Camzyos and Cytokinetics' aficamten. In heart failure with preserved ejection fraction it faces large drugmakers with established therapy classes. Since selling its muscular dystrophy business to Servier, it no longer competes directly with Sarepta Therapeutics, PTC Therapeutics or Solid Biosciences.
How has EWTX stock performed in 2026?
+
EWTX closed near $40.26 on November 20, 2026, up about 70% year to date and about 81% over the past year, within a 52-week range of roughly $19.76 to $48.78. The shares are about 9% lower over three months and roughly flat over the past month, through the Servier GRAND CANYON news and the FDA meeting update. Analysts average a target near $55.42 with a strong buy rating. Past performance does not predict future returns.
How did Edgewise do in its latest quarter?
+
In the third quarter of 2026, reported November 4, Edgewise had no product revenue and net income of about $1.17 billion, or $9.65 per diluted share, from a roughly $1.35 billion one-time gain on the Servier sale less about $155 million of tax. R&D fell to about $31.6 million from $37.5 million a year earlier, while G&A rose to about $14.6 million from $9.4 million. Cash and investments stood at about $1.74 billion on September 30, 2026.
What is EDG-15400?
+
EDG-15400 is an oral cardiac sarcomere modulator that Edgewise is testing in heart failure with preserved ejection fraction (HFpEF). The first patient was dosed in the Phase 2 EQUINOX-HFpEF trial in October 2026; it is a randomized, double-blind, placebo-controlled study in adults aged 30 to 84 with symptomatic HFpEF and an ejection fraction of at least 50%.
Why did Edgewise sell sevasemten to Servier?
+
Edgewise sold sevasemten and its muscular dystrophy business to Servier in a transaction that closed in July 2026, receiving about $1.4 billion in cash at closing, with up to about $1.1 billion of potential milestones reported. The sale funded its cardiac programs and moved the risk of the Becker readout to Servier. That readout came on November 4, 2026, when Servier said the GRAND CANYON study missed its primary endpoint, which makes the sevasemten milestones unlikely to be paid soon.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Edgewise Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.